Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Anne Beaven, MD, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT00978432
First received: September 15, 2009
Last updated: August 3, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2018
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)